Experienced in Chondrosarcoma

Dr. Rita S. Mehta

Hematology Oncology
Uc Regents
101 The City Dr S, 
Orange, CA 
Offers Telehealth
Experienced in Chondrosarcoma
Uc Regents
101 The City Dr S, 
Orange, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rita Mehta is a Hematologist Oncology provider in Orange, California. Dr. Mehta is rated as an Experienced provider by MediFind in the treatment of Chondrosarcoma. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

Her clinical research consists of co-authoring 82 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
University Of California Irvine Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

UC REGENTS
101 The City Dr S, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Development of a Quantitative Tissue Optical Index of Breast Density
Development of a Quantitative Tissue Optical Index of Breast Density
Enrollment Status: Withdrawn
Publish Date: November 02, 2022
Intervention Type: Other
Predicting Pathological Response Within the 1st Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured With Diffuse Optical Spectroscopic Imaging
Predicting Pathological Response Within the 1st Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured With Diffuse Optical Spectroscopic Imaging
Enrollment Status: Withdrawn
Publish Date: November 01, 2022
Intervention Type: Device
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting
Enrollment Status: Withdrawn
Publish Date: November 01, 2022
Intervention Type: Device
Study Phase: Not Applicable
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Enrollment Status: Withdrawn
Publish Date: October 20, 2022
Intervention Type: Device
View 7 Less Clinical Trials

82 Total Publications

Tool use increases mechanical foraging success and tooth health in southern sea otters (Enhydra lutris nereis).
Tool use increases mechanical foraging success and tooth health in southern sea otters (Enhydra lutris nereis).
Journal: Science (New York, N.Y.)
Published: May 16, 2024
Similar Doctors
Advanced in Chondrosarcoma
Dr. Arun Singh
Hematology Oncology | Hematology | Oncology
Advanced in Chondrosarcoma
Dr. Arun Singh
Hematology Oncology | Hematology | Oncology

The Regents Of The University Of California

13160 Mindanao Way, Suite 301, 
Marina Del Rey, CA 
 (34.2 miles away)
310-301-0230
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arun Singh is a Hematologist Oncology specialist and a Hematologist in Marina Del Rey, California. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Retroperitoneal Liposarcoma, Rhabdomyosarcoma Embryonal, Undifferentiated Pleomorphic Sarcoma, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration.

Advanced in Chondrosarcoma
Dr. James Hu
Oncology | Hematology | Hematology Oncology
Advanced in Chondrosarcoma
Dr. James Hu
Oncology | Hematology | Hematology Oncology

USC Care Medical Group Inc

1441 Eastlake Ave, Suite 2424, 
Los Angeles, CA 
 (26.1 miles away)
323-442-2582
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Hu is an Oncologist and a Hematologist in Los Angeles, California. Dr. Hu is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Synovial Sarcoma, and Liposarcoma.

Advanced in Chondrosarcoma
Dr. Steven S. Yu
Hematology Oncology | Hematology | Oncology
Advanced in Chondrosarcoma
Dr. Steven S. Yu
Hematology Oncology | Hematology | Oncology

Compassionate Cancer Care Medical Group Inc

4500 Brockton Ave, Suite 107, 
Riverside, CA 
 (31.9 miles away)
951-276-2760
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Yu is a Hematologist Oncology specialist and a Hematologist in Riverside, California. Dr. Yu is rated as an Advanced provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Splenic Neoplasm, Liver Cancer, Essential Thrombocythemia, and Chondrosarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehta's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile